FrancophonIA/ELRC3.0 huggingface dataset:
English: Concomitant use of Atacand with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin) may lead to increases in serum potassium in hypertensive patients.
Estonian: Arvestades kogemusi teiste reniin-angiotensiin-aldosterooni süsteemi mõjustavate ravimitega, võib Atacandi kasutamine koos kaaliumit säästvate diureetikumide, kaaliumit sisaldavate lisandite ja soolaasendajate või teiste kaaliumisisaldust suurendada võivate ravimitega (nt hepariin) viia hüpertensiivsetel patsientidel kaaliumi kontsentratsiooni suurenemisele vereseerumis.
English: Blopress 16 mg Tabletten 16 mg Tablet
Estonian: Blopress 16 mg Tabletten
English: The changes to the SPC have been taken into account in the amendments to the PL and labelling as appropriate.
Estonian: Pakendi infolehe ja pakendi märgistuse muutmisel on arvesse võetud ravimi omaduste kokkuvõttes tehtud muutusi.
English: Some people may feel tired or dizzy when taking Atacand.
Estonian: Atacandi kasutamine võib mõnedel patsientidel põhjustada väsimust või pearinglust.
English: Parapres 8 mg comprimidos 8 mg
Estonian: Parapres 8 mg comprimidos
English: Blopress 32 mg Tabletten 32 mg Tablet
Estonian: Blopress 32 mg comprimidos 32 mg
English: If this is severe you may notice tiredness, weakness, irregular heart beat or pins and needles.
Estonian: Kui see on oluline, võite te tunda väsimust, nõrkust,
English: Candesartan cilexetil is a prodrug suitable for oral use.
Estonian: Kandesartaantsileksetiil on eelravim suu kaudu manustamiseks.
English: Section 4.3 Contraindications
Estonian: Lõik 4.3
English: Of candesartan patients 33.0% (95%CI: 30.1 to 36.0) and of placebo patients 40.0% (95%CI: 37.0 to 43.1) experienced this endpoint, absolute difference 7.0% (95%CI: 11.2 to 2.8).
Estonian: 33% (95% CI: 30,1…36,0) kandesartaani patsientidest ja 40% (95% CI: 37,0…43,1) platseebo patsientidest kogesid seda tulemusnäitajat, absoluutne erinevus 7,0%
English: It is rapidly converted to the active substance, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract.
Estonian: Seedetraktist imendumisel muudetakse eelravimestri hüdrolüüsi teel kiiresti aktiivseks ravimiks kandesartaaniks.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS
Estonian: MINIMAALSED NÕUDED, MIS PEAVAD OLEMA KIRJAS BLISTERPAKENDIL Mitteperforeeritud foolium, perforeeritud foolium
English: Blopress 8 mg comprimidos 8 mg
Estonian: Blopress 8 mg comprimidos
English: Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.
Estonian: Kombineeritud ravi alustamisel ning perioodiliselt ravi jooksul on vajalik jälgida neerufunktsiooni.
English: Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.
Estonian: Atacand on näidustatud: - essentsiaalse hüpertensiooni raviks täiskasvanutel; - südamepuudulikkuse ja südame vasaku vatsakese süstoolse funktsiooni puudulikkuse (vasaku vatsakese väljutusmaht ≤40%) raviks täiskasvanutel lisaks angiotensiini konverteeriva ensüümi inhibiitorile või juhul, kui patsient ei talu angiotensiini konverteeriva ensüümi inhibiitoreid.
English: Blopress 4 mg comprimidos 4 mg
Estonian: Blopress 4 mg comprimidos
English: Frequency Undesirable Effect
Estonian: Mõju reaktsioonikiirusele
English: Atacand 4 mg comprimidos 4 mg
Estonian: Atacand 4 mg comprimidos
English: The agreed indications were:
Estonian: Inimravimite komitee poolt soovitatav näidustus on:
English: The CHMP noted that there is plausible effect based on the pharmacologic action of the drug to affect the ability to drive thus this section was harmonised to reflect that ‘dizziness' and ‘weariness' can occur.
Estonian: Inimravimite komitee märkis, et ravimi farmakoloogilist toimet arvestades on mõju autojuhtimise ja masinate kasutamise võimele üsnagi tõenäoline.
English: candesartan cilexetil
Estonian: kandesartaantsileksetiil
English: Section 4.1 Therapeutic indications
Estonian: Lõik 4.1
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Estonian: MÜÜGILOA HOIDJA NIMI JA AADRESS [Vaata Lisa I - täidetakse riiklikult]
English: Should these agents be less than effective, addition of an ARB or a potassium sparing diuretic should be considered.
Estonian: Kui nimetatud ravimite toime on ebapiisav, siis võib raviskeemi lisada angiotensiini retseptorite blokaatori või kaaliumisäästva diureetikumi.
English: No routine monitoring of laboratory variables is usually necessary for patients receiving Atacand.
Estonian: Atacandi kasutavatel patsientidel ei ole laboratoorsete näitude rutiinne monitooring vajalik.
English: BEFORE YOU TAKE ATACAND
Estonian: MIDA ON VAJA TEADA ENNE ATACANDI KASUTAMIST
English: Very rare Nausea
Estonian: Väga harv
English: 6.1 List of excipients
Estonian: FARMATSEUTILISED ANDMED 6.1 Abiainete loetelu [Täidetakse riiklikult]
English: Atacand 8 mg comprimidos 8mg
Estonian: Atacand 8 mg comprimidos
English: This is usually achieved within a month.
Estonian: See saavutatakse tavaliselt kuu aja jooksul.
English: This summary was last updated in 10-2016
Estonian: Kokkuvõtte viimane uuendus: 10-2016.
English: What measures are being taken to ensure the safe and effective use of Cystadane?
Estonian: Mis meetmeid võetakse, et tagada Cystadane ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cystadane on 15 February 2007.
Estonian: Euroopa Komisjon andis Cystadane müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. veebruaril 2007.
English: The aim of the treatment is to keep blood levels of homocysteine below 15 micromoles or as low as possible.
Estonian: Ravi eesmärk on hoida homotsüsteiini sisaldus vereplasmas alla 15 mikromooli või võimalikult väike.
English: This causes a wide range of symptoms, including impaired vision, weak bones and circulatory problems.
Estonian: See põhjustab väga mitmesuguseid sümptomeid, sealhulgas halvenenud nägemist, luude nõrkust ja verevarustusprobleeme.
English: It should be dissolved fully in water, juice, milk, formula or food immediately before being taken.
Estonian: Ravim tuleb vahetult enne võtmist täielikult lahustada vees, mahlas, piimas, toitesegus või toidus.
English: This helps to improve the symptoms of the disease.
Estonian: See aitab haigussümptomeid ohjeldada.
English: Other information about Cystadane
Estonian: Muu teave Cystadane kohta
English: Most patients were also taking vitamins B6 or B12, or folate.
Estonian: Enamik patsientidest kasutas ka B6- või B12-vitamiini või folaati.
English: The Committee noted that Cystadane is not a substitute for other treatments.
Estonian: Komitee märkis, et Cystadane ei asenda muud ravi.
English: Betaine is a natural substance that is extracted from sugar beet.
Estonian: Betaiin on looduslik aine, mida eraldatakse suhkrupeedist.
English: The medicine was effective in patients with all three types of homocystinuria.
Estonian: Ravim oli efektiivne kõiki kolme liiki homotsüstinuuriaga patsientidel.
English: What is Cystadane and what is it used for?
Estonian: Mis on Cystadane ja milleks seda kasutatakse?
English: The dose can be adjusted depending on the response to treatment (monitored by measuring the level of homocysteine in the blood).
Estonian: Annust võib kohandada ravivastuse järgi (mille jälgimiseks mõõdetakse homotsüsteiini sisaldust veres).
English: Cystadane is supplied with 3 measuring spoons to measure 100 mg, 150 mg and 1 g of the powder.
Estonian: Cystadane pakend sisaldab 3 mõõtelusikat 100 mg, 150 mg ja 1 g pulbri mõõtmiseks.
English: The information from these studies was compared to published reports describing the outcome of untreated patients with the disease.
Estonian: Neist uuringutest saadud teavet võrreldi ravimata patsientide tulemustega, mida kirjeldati avaldatud teadetes.
English: The most common side effect when taking Cystadane (seen in more than 1 patient in 10) is elevated levels of methionine in the blood.
Estonian: Cystadane kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on metioniinisisalduse suurenemine veres.
English: Why is Cystadane approved?
Estonian: Miks Cystadane heaks kiideti?
English: For 140 patients, information was also provided on their symptoms, the dose and duration of treatment, and other medicines being taken.
Estonian: Esitati ka teavet 140 patsiendi sümptomite, annuse ja ravi kestuse ning teiste kasutatavate ravimite kohta.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Cystadane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Cystadane kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: It is used with other treatments, such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a special diet.
Estonian: Cystadanet kasutatakse koos muu raviga, näiteks B6-vitamiini (püridoksiin), B12-vitamiini (kobalamiin), folaadi ja eridieediga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cystadane have also been included in the summary of product characteristics and the package leaflet.
Estonian: Cystadane ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, although there were few systematic studies of Cystadane, the medicine is useful when added to existing treatments for homocystinuria, such as vitamin supplementation and using a special diet.
Estonian: Inimravimite komitee otsustas, et kuigi Cystadane kohta on läbi viidud vähe süstemaatilisi uuringuid, on seda ravimit kasulik lisada homotsüstinuuria olemasolevale ravile, näiteks vitamiinilisandile ja eridieedi kasutamisele.
English: The full EPAR for Cystadane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cystadane kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What are the risks associated with Cystadane?
Estonian: Mis riskid Cystadanega kaasnevad?
English: The standard dose of Cystadane is 100 mg per kilogram of body weight a day, divided into two equal doses.
Estonian: Cystadane tavaannus on 100 mg kehakaalu kilogrammi kohta ööpäevas jagatuna kaheks võrdseks annuseks.
English: This was associated with an improvement in symptoms affecting the cardiovascular system (heart and blood vessels) as well as an improvement in developmental problems in around three quarters of the patients taking Cystadane.
Estonian: Seda seostati südame-veresoonkonna sümptomite ning arenguprobleemide paranemisega ligikaudu kolmveerandil Cystadanet kasutanud patsientidel.
English: Cystadane betaine anhydrous
Estonian: Cystadane veevaba betaiin
English: It is not intended to provide practical advice on how to use Cystadane.
Estonian: Hindamisaruandes ei anta Cystadane kasutamise praktilisi nõuandeid.
English: Patients with symptoms of cerebral oedema, such as morning headaches with vomiting, or changes in vision, should speak to their doctor, as treatment with Cystadane may have to be interrupted.
Estonian: Ajuturse sümptomitega, näiteks koos oksendamisega esinevate hommikuste peavaludega või nägemishäiretega patsiendid peavad pöörduma arsti poole, sest võib osutuda vajalikuks nende ravi Cystadanega katkestada.
English: Because the number of patients with homocystinuria is low, the disease is considered ‘rare', and Cystadane was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 July 2001.
Estonian: Et homotsüstinuuriaga patsientide arv on väike ja see haigus esineb harva, nimetati Cystadane 9. juulil 2001 harvikravimiks.
English: This is a summary of the European public assessment report (EPAR) for Cystadane.
Estonian: See on ravimi Cystadane Euroopa avaliku hindamisaruande kokkuvõte.
English: It recommended that Cystadane be given marketing authorisation.
Estonian: Komitee soovitas anda Cystadane müügiloa.
English: Patients taking Cystadane appeared to have greater reductions in homocysteine levels than untreated patients.
Estonian: Cystadanet kasutanud patsientidel vähenes homotsüsteiinisisaldus rohkem kui ravimata patsientidel.
English: In particular, the company will monitor cases of cerebral oedema, which was seen in a small number of patients during the testing of the medicine.
Estonian: Ettevõte jälgib eelkõige ajuturse juhtumeid, mida esines vähestel patsientidel ravimi uuringute etapil.
English: In homocystinuria, betaine reduces homocysteine levels in the blood by transforming homocysteine into the amino acid methionine.
Estonian: Homotsüstinuuria korral vähendab betaiin vere homotsüsteiinisisaldust, mille tulemusena homotsüsteiin muundub tagasi aminohappeks metioniiniks.
English: The company that makes Cystadane will set up a register of patients taking the medicine to monitor its safety.
Estonian: Cystadane tootja koostab ravimi ohutuse jälgimiseks seda ravimit kasutavate patsientide registri.
English: For practical information about using Cystadane, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Cystadane kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How is Cystadane used?
Estonian: Kuidas Cystadanet kasutatakse?
English: For more information about treatment with Cystadane, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cystadanega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This included 202 reports that described the effects of Cystadane, given at a variety of doses, on homocysteine levels in homocystinuria patients of various ages.
Estonian: Ettevõte esitas Cystadane kohta teaduskirjanduse andmeid, sealhulgas 202 teadet, milles kirjeldati mitmesugustes annustes manustatud Cystadane toimet homotsüsteiinisisaldusele eri vanuses homotsüstinuuria patsientidel.
English: Cystadane is a medicine used to treat homocystinuria, an inherited disease where the amino acid homocysteine cannot be broken down and therefore builds up in the body.
Estonian: Homotsüstinuuria on pärilik haigus, kus organism ei suuda aminohapet homotsüsteiini lagundada, mille tulemusena selle sisaldus organismis tõuseb.
English: Cystadane contains the active substance betaine anhydrous.
Estonian: Cystadane sisaldab toimeainena veevaba betaiini.
English: How does Cystadane work?
Estonian: Kuidas Cystadane toimib?
English: The Committee decided that Cystadane's benefits outweighed its risks in the adjunctive treatment of homocystinuria, when it is used according to its indication.
Estonian: Komitee leidis, et Cystadane kasulikkus kasutamisel vastavalt näidustusele homotsüstinuuria täiendava ravina on suurem kui sellega kaasnevad riskid.
English: What benefits of Cystadane have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cystadane kasulikkus?
English: Treatment with Cystadane should be supervised by a doctor who has experience in the treatment of patients with homocystinuria.
Estonian: Ravi Cystadanega peab toimuma homotsüstinuuriaga patsientide ravi kogemusega arsti järelevalve all.
English: Cystadane is available as a powder to be taken by mouth.
Estonian: Cystadanet turustatakse suukaudse pulbrina.
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Cystadane kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Methionine levels should be monitored in patients taking Cystadane, as it might lead to cerebral oedema (swelling in the brain).
Estonian: Cystadanet kasutavatel patsientidel tuleb jälgida metioniinisisaldust, sest see võib tekitada ajuturse.
English: The full EPAR for Bridion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Bridioni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Bridion is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Bridioni võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Bridion?
Estonian: Mis meetmed võetakse, et tagada Bridioni ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Bridion on 25 July 2008.
Estonian: Euroopa Komisjon andis Bridioni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 25. juulil
English: This dose is expected to be used in only a limited number of the treatments (less than 1%).
Estonian: Eeldatavalt on seda annust vaja kasutada harva (alla 1% juhtudest).
English: This might be necessary if patients need to be able to start to breathe on their own again during the operation.
Estonian: Seda võib olla vaja patsiendi iseseisva hingamise taastamiseks operatsiooni ajal.
English: Other information about Bridion
Estonian: Muu teave Bridioni kohta
English: There were too few children aged below two years to determine the safety and effectiveness of Bridion in this age group.
Estonian: Uuringus osales liiga vähe alla 2-aastasi lapsi, et selgitada Bridioni ohutust ja efektiivsust selles vanuserühmas.
English: The CHMP decided that Bridion's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Bridioni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Bridion.
Estonian: See on ravimi Bridion Euroopa avaliku hindamisaruande kokkuvõte.
English: Bridion is a solution for injection that contains the active substance sugammadex (100 mg/ml).
Estonian: Bridion on süstelahus, mis sisaldab toimeainena sugammadeksi (100 mg/ml).
English: The most common side effects with Bridion (seen in between 1 and 10 patients in 100) are cough, airway problems due to the anaesthesia wearing off, reduced blood pressure and other complications such as changes in heart rate.
Estonian: Bridioni kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on köha, hingamishäired anesteesia lõppemisel, vähenenud vererõhk ja muud tüsistused, näiteks südame löögisageduse muutused.
English: Bridion is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.
Estonian: Bridioni kasutatakse taastumise kiirendamiseks pärast müorelaksantide kasutamist, tavaliselt operatsiooni lõpus.
English: In contrast, muscle relaxation recovered spontaneously after 7.1 minutes.
Estonian: Spontaanselt taandus lihaslõõgastus 7,1 minuti pärast.
English: Muscle relaxants make it easier for the surgeon to do the operation.
Estonian: Müorelaksandid lihtsustavad operatsiooni tegemist.
English: Bridion has been studied in four main studies in a total of 579 adults undergoing surgery using muscle relaxants.
Estonian: Bridioni uuriti neljas põhiuuringus kokku 579 täiskasvanud patsiendil, kelle opereerimisel kasutati müorelaksante.
English: What is Bridion?
Estonian: Mis on Bridion?
English: An additional study looked at the effectiveness of Bridion given after rocuronium in 90 children and adolescents.
Estonian: Veel ühes uuringus vaadeldi Bridioni efektiivsust pärast rokurooniumi manustamist 90 lapsel ja noorukil.
English: For more information about treatment with Bridion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Bridioniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bridion, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Bridioni omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bridion.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Bridion can be used in adults who have received rocuronium and vecuronium, and in children and adolescents who have received rocuronium.
Estonian: Bridioni tohib kasutada täiskasvanutel, kellele on manustatud rokurooniumi ja vekurooniumi, ning lastel ja noorukitel, kellele on manustatud rokurooniumi.
English: For the full list of all side effects reported with Bridion, see the package leaflet.
Estonian: Bridioni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is the risk associated with Bridion?
Estonian: Mis riskid Bridioniga kaasnevad?
English: Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe.
Estonian: Müorelaksandid (lihaselõõgastid) on ravimid, mida kasutatakse teatud tüüpi operatsioonide ajal lihaste, sealhulgas hingamislihaste lõõgastamiseks.
English: In all of the studies, the main measure of effectiveness was how long it took for the muscles to recover.
Estonian: Kõigis uuringutes oli efektiivsuse põhinäitaja aeg, mille jooksul taastus normaalne lihasetalitlus.
English: In children and adolescents from two to 17 years of age, the recommended dose is 2 mg/kg body weight.
Estonian: 2-17-aastastel lastel ja noorukitel on soovitatav annus 2 mg kehamassi kg kohta.
English: The standard dose of Bridion is between 2 and 4 mg per kilogram body weight, depending on how much the muscle relaxant is affecting the muscles.
Estonian: Bridioni tavaannus on 2-4 mg kehamassi kg kohta, sõltuvalt sellest, kuidas müorelaksant lihastele mõjub.
English: Bridion must not be used in people who are hypersensitive (allergic) to sugammadex or any of the other ingredients.
Estonian: Bridioni ei tohi kasutada patsiendid, kes on sugammadeksi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Why has Bridion been approved?
Estonian: Miks Bridion heaks kiideti?
English: This means that it attaches to the muscle relaxants rocuronium and vecuronium forming a ‘complex' that inactivates the muscle relaxants and stops them having an effect.
Estonian: See tähendab, et ravim seondub müorelaksantide rokurooniumi ja vekurooniumi molekuliga, moodustades kompleksi, mis inaktiveerib müorelaksandid ja peatab nende toime.
English: Bridion can only be given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia).
Estonian: Bridioni tohib manustada ainult anestesioloog (anesteesia (narkoosi) tegemise eriarst) või anestesioloogi järelevalve all.
English: As a result, the effect of blockade of the muscles due to rocuronium and vecuronium on the muscles is reversed, and the muscles begin to work normally again, including the muscles that help the patient to breathe.
Estonian: Selle tulemusena lõpeb rokurooniumi ja vekurooniumi blokeeriv toime lihastele ning lihased, sealhulgas hingamislihased, hakkavad uuesti normaalselt tööle.